Review article: autoimmune hepatitis - current management and challenges
The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Autoimmune hepatitis (AIH) is a disease of unknown aetiology characterised by interface hepatitis, hypergammaglobulinaemia, circulating autoantibodies and a favourable response to immunosuppression. AIM: To review recent advancements in understanding aetiopathogenesis, clinical, serological and histological features, diagnostic criteria and treatment strategies of AIH. METHODS: Published studies on AIH extracted mainly from PubMed during the last 15 years. RESULTS: Autoimmune hepatitis has a global distribution affecting any age, both sexes and all ethnic groups. Clinical manifestations are variable ranging from no symptoms to severe acute hepatitis and only seldom to fulminant hepatic failure. Autoimmune attack is perpetuated, possibly via molecular mimicry mechanisms, and favoured by the impaired control of regulatory T-cells. A typical laboratory finding is hypergammaglobulinaemia with selective elevation of IgG, although in 15-25% of patients - particularly children, elderly and acute cases - IgG levels are normal. Liver histology and autoantibodies, although not pathognomonic, still remain the hallmark for diagnosis. Immunosuppressive treatment is mandatory and life-saving; however, to meet strict response criteria, the conventional therapy with prednisolone with or without azathioprine is far from ideal. CONCLUSIONS: Autoimmune hepatitis remains a major diagnostic and therapeutic challenge. The clinician, the hepato-pathologist and the laboratory personnel need to become more familiar with different expressions of the disease, interpretation of liver histology and autoimmune serology. According to the strict definition of treatment response issued by the 2010 AASLD guidelines, many patients are nonresponders to conventional treatment. Newer immunosuppressive agents targeting pathogenetic mechanisms can improve patient management, which needs to be tailored on a case-by-case basis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Alvarez, F., Berg, P. A., Bianchi, F. B., Bianchi, L., Burroughs, A. K., Cancado, E. L., Chapman, R. W., Cooksley, W. G. E., Czaja, A. J., Desmet, V. J., et al. (1999) · Journal of Hepatology · doi:10.1016/s0168-8278(99)80297-9 · Cited by 2,903
Simplified criteria for the diagnosis of autoimmune hepatitis
Hennes, E. M., Zeniya, M., Czaja, A. J., Parés, A., Dalekos, G. N., Krawitt, E. L., Bittencourt, P. L., Porta, G., Boberg, K. M., Hofer, H., et al. (2008) · Hepatology · doi:10.1002/hep.22322 · Cited by 1,901
Self-citationDiagnosis and management of autoimmune hepatitis
Manns, M. P., Czaja, A. J., Gorham, J. D., Krawitt, E. L., Mieli-Vergani, G., Vergani, D., & Vierling, J. M. (2010) · Hepatology · doi:10.1002/hep.23584 · Cited by 1,442
Chazouillères, O., Wendum, D., Serfaty, L., Montembault, S., Rosmorduc, O., & Poupon, R. (1998) · Hepatology · doi:10.1002/hep.510280203 · Cited by 746
Gregorio, G. (2001) · Hepatology · doi:10.1053/jhep.2001.22131 · Cited by 692
Boberg, K. M., Chapman, R. W., Hirschfield, G. M., Lohse, A. W., Manns, M. P., & Schrumpf, E. (2011) · Journal of Hepatology · doi:10.1016/j.jhep.2010.09.002 · Cited by 555 · cited 3×
“the ground that the definition of the diagnostic criteria for overlap conditions can only be arbitrary.(182) In addi-”
BackgroundResultInfluentialMechanisms of action of mycophenolate mofetil
Allison, A. (2005) · Lupus · doi:10.1177/096120330501400102 · Cited by 480
Kuo, T. K., Hung, S., Chuang, C., Chen, C., Shih, Y. V., Fang, S. Y., Yang, V. W., & Lee, O. K. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.03.015 · Cited by 466
Vergani, D., Alvarez, F., Bianchi, F. B., Cançado, E. L. R., Mackay, I. R., Manns, M. P., Nishioka, M., & Penner, E. (2004) · Journal of Hepatology · doi:10.1016/j.jhep.2004.08.002 · Cited by 446 · cited 1×
“tion of serum samples, optimal dilution, fluorochrome-labelled revealing agents, selection of controls and diagnostically relevant staining patterns.(93) IIF on fresh frozen sections (of 4–8 weeks store) of a multiorgan substrate from rodents, especially rats, is ideally the”
BackgroundLong-term follow-up of antimitochondrial antibody-positive autoimmune hepatitis
O'Brien, C., Joshi, S., Feld, J. J., Guindi, M., Dienes, H. P., & Heathcote, E. J. (2008) · Hepatology · doi:10.1002/hep.22380 · Cited by 146 · cited 1×
“overt AIH who tested AMA-positive and are treated with corticosteroids had no clinical or histological evidence of PBC, despite the continued detection of AMA over a follow-up of up to 27 years.(161) In contrast, a recent small”
ResultThe serological profile of the autoimmune hepatitis/primary biliary cirrhosis overlap syndrome
Muratori, P., Granito, A., Pappas, G., Pendino, G. M., Quarneti, C., Cicola, R., Menichella, R., Ferri, S., Cassani, F., Bianchi, F. B., et al. (2009) · The American Journal of Gastroenterology · doi:10.1038/ajg.2009.126 · Cited by 125
Self-citationKido, M., Watanabe, N., Okazaki, T., Akamatsu, T., Tanaka, J., Saga, K., Nishio, A., Honjo, T., & Chiba, T. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.06.042 · Cited by 119
Autoimmune hepatitis-PBC overlap syndrome: a simplified scoring system may assist in the diagnosis
Neuhauser, M., Bjornsson, E., Treeprasertsuk, S., Enders, F., Silveira, M., Talwalkar, J., & Lindor, K. (2010) · American Journal of Gastroenterology · doi:10.1038/ajg.2009.616 · Cited by 116
GRANITO, A., MURATORI, P., MURATORI, L., PAPPAS, G., CASSANI, F., WORTHINGTON, J., FERRI, S., QUARNETI, C., CIPRIANO, V., DE MOLO, C., et al. (2007) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2007.03433.x · Cited by 102
Self-citationPresence of antimitochondrial autoantibodies in patients with autoimmune hepatitis
Nezu, S., Tanaka, A., Yasui, H., Imamura, M., Nakajima, H., Ishida, H., & Takahashi, S. (2006) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2006.04434.x · Cited by 52 · cited 1×
“6% to as high 34% 165 in Japanese patients.(158) Most studies agree that AMA detection in AIH does not identify a subgroup that requires different treatment or that evolves quickly into a cholestatic syndrome.”
Background
Cited by
EASL Clinical Practice Guidelines: autoimmune hepatitis
(2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.06.030 · Cited by 1,245
“030 6 Journal of Hepatology 201 been reported [3,4,85,86].”
BackgroundInfluentialMieli‐Vergani, G., Vergani, D., Baumann, U., Czubkowski, P., Debray, D., Dezsofi, A., Fischler, B., Gupte, G., Hierro, L., Indolfi, G., et al. (2018) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1097/mpg.0000000000001801 · Cited by 356
Than, N. N., Hodson, J., Schmidt-Martin, D., Taubert, R., Wawman, R. E., Botter, M., Gautam, N., Bock, K., Jones, R., Appanna, G. D., et al. (2019) · JHEP Reports · doi:10.1016/j.jhepr.2019.10.005 · Cited by 101
“Rituximabhas been licenced for clinical use in adultswith CD20positive B cell lymphoma, rheumatoid arthritis, or vasculitis associated with anti-neutrophil cytoplasmic antibodies.(20) However, rituximab is not currently a licenced therapy in AIH and representative, multicentre, long-term data on the efficacy of rituxi…”
BackgroundWang, J., Ma, Z., Niu, M., Zhu, Y., Liang, Q., Zhao, Y., Song, J., Bai, Z., Zhang, Y., Zhang, P., et al. (2015) · Frontiers of Medicine · doi:10.1007/s11684-015-0417-8 · Cited by 70
Muratori, P., Efe, C., Muratori, L., Ozaslan, E., Schiano, T., Yoshida, E. M., Heurgué-Berlot, A., Lalanne, C., Lenzi, M., & Wahlin, S. (2017) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000000870 · Cited by 19
Self-citation
Metadata
- Authors
- Zachou, K., Muratori, P., Koukoulis, G. K., Granito, A., Gatselis, N., Fabbri, A., Dalekos, G. N., & Muratori, L.
- Venue
- Alimentary Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 2013-09-08
- Volume
- 38
- Issue
- 8
- Pages
- 887-913
- ISSN
- 0269-2813 (ISSN-L)
- OpenAlex
- W1996015553
- Cited by
- 179
- References
- 15
- FWCI
- 9.18
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.